Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III adjuvant foritinib succinate versus platinum-based chemotherapy after complete resection in ALK- or ROS1-positive NSCLC
CTR20253447Phase 3Active
- Sponsor
- Wanbang Biopharmaceuticals
- Start
- Aug 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of foritinib in non-small cell lung cancer (NSCLC), sponsored by Wanbang Biopharmaceuticals. Started Aug 2025; status: active.
02
Drugs
foritinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20253447.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253447.